Diacetylcurcumin: Its Potential Antiarthritic Effect on a Freund's Complete Adjuvant-Induced Murine Model

• Published in: Molecules (Basel, Switzerland) Vol. 24; no. 14; p. 2643
• Main Authors: Escobedo-Martínez, Carolina, Guzmán-Gutiérrez, Silvia Laura, Carrillo-López, María Isabel, Deveze-Álvarez, Martha Alicia, Trujillo-Valdivia, Alfonso, Meza-Morales, William, Enríquez, Raúl G
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.07.2019; MDPI
• Subjects: Acetylation; Animal models; Animals; Anti-Inflammatory Agents - chemistry; Anti-Inflammatory Agents - pharmacology; antiarthritic; Arthritis; Arthritis, Experimental - drug therapy; Arthritis, Experimental - etiology; Arthritis, Experimental - pathology; Bioavailability; Biological models (mathematics); Chromatography, High Pressure Liquid; Curcumin; Curcumin - analogs & derivatives; Curcumin - chemistry; Curcumin - pharmacology; diacetylcurcumin; Disease Models, Animal; Drug dosages; Edema; Experiments; Freund's Adjuvant - adverse effects; Freund’s complete adjuvant; Inflammation; Kinases; Magnetic Resonance Spectroscopy; Medical research; Mice; Oral administration; Phenolic compounds; Phenols; Rats; Rheumatoid arthritis; Staphylococcus infections; Treatment Outcome; Freund’s complete adjuvant; antiarthritic; diacetylcurcumin; curcumin
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules24142643

The present study aims to evaluate the antiarthritic activity of diacetylcurcumin (DAC), a synthetic derivative where the free phenolic groups of curcumin are derivatized by acetylation, thereby conferring greater lipophilicity to the parent molecule and partially overcoming the limited systemic bioavailability of curcumin. Antiarthritic activity was evaluated on a Freund's complete adjuvant (FCA)-induced murine model of arthritis. Oral administration of DAC (60 and 120 mg/kg) resulted in a significant inhibition of inflammation in the acute and chronic phases, respectively, demonstrating an improved and sustained anti-inflammatory effect, comparable to that of curcumin (150 mg/kg) in the chronic stage at a lower dose. Phenylbutazone (80 mg/kg) was used as a reference drug. The pharmacological consequence of DAC or curcumin treatment is the prevention of secondary lesions commonly associated with this biological model.